Flumequine: High-Purity DNA Topoisomerase II Inhibitor for Research

Executive Summary: Flumequine is a synthetic small-molecule inhibitor with high specificity for DNA topoisomerase II (IC50 ≈ 15 μM), enabling precise studies of DNA replication and enzyme inhibition (product_spec). The compound is chemically stable when stored at -20°C and is supplied at >98% purity, verified by HPLC and mass spectrometry analyses (product_spec). Flumequine is insoluble in water and ethanol but dissolves in DMSO at ≥9.35 mg/mL, supporting diverse assay workflows (product_spec). Its use is recommended for DNA replication research, topoisomerase II inhibition assays, and cancer studies modeling DNA damage and repair (Schwartz 2022). APExBIO supplies Flumequine (SKU B2292) as a ready-to-use, high-purity research compound.

Biological Rationale

DNA topoisomerase II is an essential enzyme that modulates the topological states of DNA during replication and transcription. Dysregulation of this enzyme is linked to genomic instability and cancer progression (Schwartz 2022). Small-molecule inhibitors like Flumequine allow researchers to dissect the pathways governing DNA breakage, repair, and cell cycle control. Use of potent, defined inhibitors is critical for quantifying DNA replication arrest and cytotoxicity in vitro (internal).

Mechanism of Action of Flumequine

Flumequine is a 9-fluoro-5-methyl-1-oxo-1,5,6,7-tetrahydropyrido[3,2,1-ij]quinoline-2-carboxylic acid compound (product_spec). It binds to the ATPase domain of DNA topoisomerase II, stabilizing the transient DNA cleavage complex. This action prevents religation of DNA double-strand breaks, leading to accumulation of DNA damage and ultimately cell cycle arrest and cytotoxicity (Schwartz 2022). The molecular weight is 261.25 g/mol, and the compound’s selective mechanism underpins its value for mechanistic enzyme inhibition studies.

Evidence & Benchmarks

• Flumequine inhibits DNA topoisomerase II with an IC50 of approximately 15 μM in cell-free enzyme assays (source: product_spec).
• Supplied with ≥98% purity as verified by HPLC and mass spectrometry (source: product_spec).
• Stable as a solid at -20°C for at least 24 months; solutions are not recommended for long-term storage (source: product_spec).
• Soluble in DMSO at ≥9.35 mg/mL but insoluble in water or ethanol (source: product_spec).
• Validated for use in DNA replication inhibition assays and cancer drug response models (source: Schwartz 2022).

This article extends the bench-focused guidance in "Flumequine: DNA Topoisomerase II Inhibitor for Precision Assays" by contextualizing purity and stability controls for reproducible results in broader DNA replication and repair studies. For systems-level perspectives, see "Flumequine: Advanced Insights into DNA Topoisomerase II Inhibition", which this article updates with current product verification and workflow integration strategies. Additional protocol optimization is detailed in "Optimizing DNA Topoisomerase II Assays: Flumequine (SKU B2292)".

Applications, Limits & Misconceptions

Flumequine is employed primarily in topoisomerase II inhibition assays, DNA replication research, and studies on DNA damage and repair. Its defined IC50 allows for quantitative modeling of dose–response relationships in cultured cells and cell-free systems (Schwartz 2022). The compound is not recommended for in vivo studies due to solubility and pharmacokinetic limitations (workflow_recommendation).

Common Pitfalls or Misconceptions

• Flumequine is not effective as an antibiotic in clinical settings due to resistance and pharmacokinetics (source: product_spec).
• The compound’s insolubility in water and ethanol limits its use to DMSO-based protocols (source: product_spec).
• Long-term storage of Flumequine solutions is not recommended; prepare fresh solutions for each experiment (source: product_spec).
• Using Flumequine outside recommended assay concentrations (<1 μM or >100 μM) may yield non-specific or artifactual results (workflow_recommendation).
• Do not extrapolate in vitro findings directly to in vivo efficacy without supporting pharmacological data (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• topoisomerase II inhibition assay | 15 μM (IC50) | cell-free and cell-based systems | Standard for benchmarking DNA topoisomerase II inhibition | product_spec
• DNA replication arrest assay | 10–50 μM | mammalian cell culture | Enables dose-response curve generation for cytotoxicity | product_spec
• Solvent compatibility | DMSO ≥9.35 mg/mL | All in vitro protocols | Ensures complete dissolution and assay reproducibility | product_spec
• Storage condition | -20°C (solid) | All applications | Maintains compound stability for ≥24 months | product_spec
• Solution stability | <1 week at -20°C | Fresh prep recommended | Prevents degradation and loss of activity | workflow_recommendation

For further optimization and troubleshooting guidance, researchers can consult "Optimizing DNA Topoisomerase II Assays: Flumequine (SKU B2292)".

Conclusion & Outlook

Flumequine, as provided by APExBIO, is a validated DNA topoisomerase II inhibitor with precise purity and solubility controls, supporting advanced DNA replication and repair studies (product_spec). Its defined inhibition parameters and storage recommendations enable reproducible bench research. Current evidence supports its role in in vitro modeling of DNA damage response and anti-cancer drug evaluation (Schwartz 2022). Ongoing integration with quantitative assay systems will extend its utility in mechanistic and therapeutic research domains.